NortonLifeLock (NLOK) Competitors

NortonLifeLock (NASDAQ:NLOK) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both information companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Does the MarketBeat Community believe in NLOK or BTX?

NortonLifeLock received 81 more outperform votes than Brooklyn ImmunoTherapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave NortonLifeLock an outperform vote while only 0.00% of users gave Brooklyn ImmunoTherapeutics an outperform vote.

Company	Underperform	Outperform
NortonLifeLock	Outperform Votes 81 100.00%	Underperform Votes No Votes
Brooklyn ImmunoTherapeutics	Outperform Votes No Votes	Underperform Votes 99 100.00%

Is NLOK or BTX more profitable?

Company	Net Margins	Return on Equity	Return on Assets
NortonLifeLock	N/A	N/A	N/A
Brooklyn ImmunoTherapeutics	N/A	N/A	N/A

Which has more volatility and risk, NLOK or BTX?

NortonLifeLock has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, suggesting that its stock price is 361% more volatile than the S&P 500.

Which has stronger earnings and valuation, NLOK or BTX?

NortonLifeLock has higher revenue and earnings than Brooklyn ImmunoTherapeutics. Brooklyn ImmunoTherapeutics is trading at a lower price-to-earnings ratio than NortonLifeLock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NortonLifeLock	$2.82B	5.64	$817.05M	$1.43	19.46
Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	-$2.27	-0.11

Does the media refer more to NLOK or BTX?

In the previous week, NortonLifeLock and NortonLifeLock both had 1 articles in the media. NortonLifeLock's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NortonLifeLock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brooklyn ImmunoTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders have more ownership in NLOK or BTX?

94.9% of NortonLifeLock shares are owned by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 3.3% of NortonLifeLock shares are owned by company insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

NortonLifeLock beats Brooklyn ImmunoTherapeutics on 6 of the 8 factors compared between the two stocks.